Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effect of gestational age on major neurodevelopmental disorders in preterm infants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Blood transcriptomic markers of necrotizing enterocolitis in preterm pigs

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictors of outcome in children with disorders of mitochondrial metabolism in the pediatric intensive care unit

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Tereza Lerchova
  • Ondrej Hradsky
  • Michal Kulich
  • Gabor Veres
  • Jorge Amil Dias
  • Małgorzata Sładek
  • Sanja Kolacek
  • Stephanie Van Biervliet
  • Jan Melek
  • Daniela E Serban
  • Katrine Winther
  • Tim de Meij
  • Jan Schwarz
  • Kaija-Leena Kolho
  • Johanna C Escher
  • Jiri Bronsky
View graph of relations

BACKGROUND: Maintaining of remission early in the disease course of Crohn's disease (CD) is essential and has major impact on the future prognosis. This study aimed to identify baseline predictors to develop model allowing stratification of patients who will not benefit from long-term azathioprine (AZA) treatment and will require more intensive therapy.

METHODS: This study was designed to develop clinical prediction rule using retrospective data analysis of pediatric CD patients included in prospective inception cohort. Clinical relapse was defined as necessity of re-induction of remission. Sequence of Cox models was fitted to predict risk of relapse.

RESULTS: Out of 1190 CD patients from 13 European centers, 441 were included, 50.3% patients did not experience clinical relapse within 2 years of AZA treatment initiation. Median time to relapse was 2.11 (CI 1.59-2.46) years. Of all the tested parameters available at diagnosis, six were significant in multivariate analyses: C-reactive protein (p = 0.038), body mass index Z-score >0.8 SD (p = 0.002), abnormal sigmoid imaging (p = 0.039), abnormal esophageal endoscopy (p = 0.005), ileocolonic localization (p = 0.023), AZA dose in specific age category (p = 0.031).

CONCLUSIONS: Although the possibility of predicting relapse on AZA treatment appears limited, we developed predictive model based on six baseline parameters potentially helpful in clinical decision.

IMPACT: The possibility of predicting relapse on AZA treatment appears to be possible but limited. We identified six independent predictors available at diagnosis of early AZA/6-MP treatment failure in pediatric CD patients. Using combination of these factors, a model applicable to clinical practice was created. A web-based tool, allowing estimation of individual relapse risk in pediatric CD patients on a particular therapeutic regimen, has been developed.

Original languageEnglish
JournalPediatric Research
ISSN0031-3998
DOIs
Publication statusE-pub ahead of print - 25 Aug 2022

Bibliographical note

© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

ID: 80527385